Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12270110 | 0.86 | ALDH1A1 (0.56) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL1119249 | 0.84 | ALOX5 (0.54) | MEN1KMT2AALDH1A1TDP1RECQL | |
| SCHEMBL14390273 | 0.78 | ABL1 (0.55) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL29913371 | 0.78 | ABL1 (0.55) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL8990149 | 0.77 | GABRA1 (0.52) | ALDH1A1MAPTKDM4ETDP1RECQL | |
| SCHEMBL7876789 | 0.77 | POLB (0.46) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL21486892 | 0.76 | GAA (0.35) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL18419016 | 0.76 | ALOX5 (0.69) | ALDH1A1KDM4EGAASMN1; SMN2ALOX5 | |
| SCHEMBL5035434 | 0.76 | CA2 (0.46) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL6833544 | 0.75 | NR5A1 (0.45) | MAPTGAATHRBBLMCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145621-A1 | 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS | INCYTE HOLDINGS CORPORATION | 2025-05-08 | — | — | US | disclosed |
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS | 2025-04-10 | — | — | US | disclosed |
| WO-2025049994-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2025-03-04 | — | — | US | disclosed |
| US-12227502-B2 | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c] pyridin-7(6H)-ones as inhibitors of BET proteins | INCYTE CORPORATION (US) | 2025-02-18 | — | — | US | disclosed |
| US-20240335442-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | UNIVERSIDADE FEDERAL DO RIO DE JANEIRO – UFRJ (BR) | 2024-10-10 | — | — | US | disclosed |
| EP-4382100-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | Eurofarma Laboratórios S.A. (BR) | 2024-06-12 | — | — | EP | disclosed |
| CN-118076348-A | N-acylhydrazone compounds capable of inhibiting NAV 1.7 and/or NAV 1.8, methods of making, compositions, uses, methods of treatment and kits using the same | 欧罗法玛实验室股份公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20240002381-A1 | 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS | INCYTE CORPORATION | 2024-01-04 | — | — | US | disclosed |
| EP-4218766-A1 | 1H-PYRROLO[2,3-C]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-C]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS | Incyte Holdings Corporation (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20050080117-A1 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2005-04-14 | — | — | US | disclosed |
| US-6794403-B2 | FOR TREATING OR INHIBITING INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, ULCERATIVE PROCTITIS OR COLITIS PROSTATIC HYPERTROPHY, UTERINE LEIOMYOMAS, BREAST CANCER, ENDOMETRIAL CANCER, CARDIOVASCULAR DISEASE, ALZHEIMER'S DISEASE | WYETH | 2004-09-21 | — | — | US | disclosed |
| EP-1451165-A1 | SUBSTITUTED BENZOXAZOLES AND ANALOGUES AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040102435-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | disclosed |
| WO-2004041792-A1 | SUBSTITUTED BENZOXAZINONES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-21 | — | — | WO | disclosed |
| US-20040092512-A1 | Substituted benzoxazinones and uses thereof | ROCHE PALO ALTO LLC | 2004-05-13 | — | — | US | disclosed |
| US-20030199562-A1 | Substituted benzoxazoles as estrogenic agents | WYETH | 2003-10-23 | — | — | US | disclosed |
| EP-1345914-A1 | THERAPEUTIC COMPOUNDS | AstraZeneca AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| WO-2003050095-A1 | SUBSTITUTED BENZOXAZOLES AND ANALOGUES AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2002051821-A1 | THERAPEUTIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080117-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | MEN1 3129/4885KMT2A 421/4885ALDH1A1 1038/4885 |
| US-20240335442-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | SCN1A, SCN7A, SCN8A | MEN1 2491/4885KMT2A 1963/4885ALDH1A1 320/4885 |
| US-20040102435-A1 | Therapeutic compounds | ESRRA, ESRRG, ESR2 | MEN1 915/4885KMT2A 2950/4885ALDH1A1 484/4885 |
| US-20240002381-A1 | 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS | BRD3, BRD1, BRD2 | MEN1 2471/4885KMT2A 655/4885ALDH1A1 4197/4885 |
| US-20250145621-A1 | 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS | BRD3, BRD1, BRD2 | MEN1 2471/4885KMT2A 655/4885ALDH1A1 4197/4885 |
| US-20030199562-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | MEN1 3728/4885KMT2A 907/4885ALDH1A1 875/4885 |
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | EP300, CREBBP, HDAC1 | MEN1 2485/4885KMT2A 689/4885ALDH1A1 1582/4885 |
| US-20040092512-A1 | Substituted benzoxazinones and uses thereof | CYP4X1, CYP3A5, CYP2D6 | MEN1 2058/4885KMT2A 2175/4885ALDH1A1 389/4885 |
| US-12227502-B2 | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c] pyridin-7(6H)-ones as inhibitors of BET proteins | BRD3, BRD1, BRD2 | MEN1 2471/4885KMT2A 655/4885ALDH1A1 4197/4885 |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | CCR1, SSB, C5 | MEN1 2779/4885KMT2A 2306/4885ALDH1A1 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.